Depressive Disorder, Treatment-Resistant
Information
- Disease name
- Depressive Disorder, Treatment-Resistant
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04159012 | Active, not recruiting | N/A | NESBID: Neuro-Stimulation of the Brain in Depression | September 1, 2020 | December 1, 2024 |
| NCT02942368 | Active, not recruiting | N/A | Adaptive tDCS for Treatment-Resistant MDD | April 14, 2017 | June 2024 |
| NCT03360942 | Active, not recruiting | Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression | April 18, 2016 | November 22, 2028 | |
| NCT03829579 | Approved for marketing | Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) | |||
| NCT02422186 | Completed | Phase 3 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression | August 20, 2015 | August 10, 2017 |
| NCT02452892 | Completed | N/A | Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) | September 2015 | October 2016 |
| NCT02493868 | Completed | Phase 3 | A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | October 1, 2015 | February 16, 2018 |
| NCT02577250 | Completed | Phase 1 | Ketamine Infusions for PTSD and Treatment-Resistant Depression | May 2015 | July 2016 |
| NCT01179009 | Completed | N/A | Treatment Resistant Depression (Pilot) | April 2012 | June 5, 2015 |
| NCT02691520 | Completed | Epidemiology of Treatment Resistant Depression in Taiwan | September 2015 | February 2016 | |
| NCT02782104 | Completed | Phase 3 | A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | June 9, 2016 | December 30, 2022 |
| NCT04216888 | Completed | Phase 2/Phase 3 | Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine | June 26, 2019 | December 28, 2020 |
| NCT03109002 | Completed | An Epidemiology Study of Treatment Resistant Depression in the United States (US) | January 15, 2017 | May 18, 2017 | |
| NCT03207282 | Completed | Treatment Resistant Depression in America Latina | September 27, 2017 | November 25, 2019 | |
| NCT03283670 | Completed | Phase 2 | Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies | November 22, 2016 | February 18, 2020 |
| NCT03373253 | Completed | Treatment-Resistant Depression Cohort in Europe | February 13, 2018 | January 24, 2020 | |
| NCT03434041 | Completed | Phase 3 | A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | May 25, 2018 | April 13, 2021 |
| NCT04977674 | Completed | Early Phase 1 | Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine | September 27, 2021 | February 20, 2023 |
| NCT03756129 | Completed | Phase 2 | Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression | February 8, 2019 | March 23, 2020 |
| NCT03051256 | Completed | Phase 2 | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD | May 11, 2018 | September 30, 2019 |
| NCT04239651 | Completed | N/A | rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) | October 15, 2020 | July 29, 2022 |
| NCT01983904 | Completed | N/A | DBS for Treatment Resistant Depression | August 2013 | March 2018 |
| NCT02153502 | Completed | Phase 2 | Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment | July 2014 | February 2016 |
| NCT04701866 | Completed | N/A | Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression | January 11, 2021 | August 24, 2022 |
| NCT04599855 | Completed | Phase 4 | A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression | November 4, 2020 | January 31, 2024 |
| NCT01898429 | Completed | N/A | Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) | July 2013 | December 2016 |
| NCT05581797 | Enrolling by invitation | N/A | Psilocybin-assisted Interpersonal Therapy for Depression | March 15, 2023 | March 2024 |
| NCT05887310 | Enrolling by invitation | In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells | August 5, 2022 | August 5, 2024 | |
| NCT06431386 | Recruiting | N/A | Behavioural Activation Therapy and Esketamine for Resistant Depression | June 2024 | August 2026 |
| NCT03851380 | Recruiting | Improving Brain Stimulation Through Imaging | September 30, 2019 | May 1, 2025 | |
| NCT04469959 | Recruiting | Phase 2 | Dopaminergic Dysfunction in Late-Life Depression | February 15, 2021 | June 30, 2026 |
| NCT04783103 | Recruiting | N/A | Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study | May 7, 2021 | July 2026 |
| NCT04956016 | Recruiting | N/A | Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment | August 23, 2021 | November 2024 |
| NCT05117710 | Recruiting | Phase 1 | IMPase in Treatment-resistant Depression | April 22, 2021 | May 31, 2024 |
| NCT05570344 | Recruiting | N/A | rTMS With and Without Text4Support for the Treatment of Resistant Depression. | February 1, 2023 | December 20, 2025 |
| NCT05641623 | Recruiting | Phase 2 | OSU6162 as add-on in SSRI/SNRI-resistant Depression | April 21, 2022 | August 31, 2026 |
| NCT05870501 | Recruiting | N/A | Synaptic Imaging and Network Activity in Treatment Resistant Depression | October 20, 2021 | September 11, 2023 |
| NCT06110507 | Recruiting | Chronic Anergic-anhedonic Depression Open Trial | April 1, 2023 | March 22, 2024 | |
| NCT06323486 | Recruiting | N/A | Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression | April 1, 2024 | March 30, 2026 |
| NCT03887624 | Terminated | Early Phase 1 | Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. | May 21, 2019 | April 1, 2021 |
| NCT02994433 | Terminated | Phase 1 | NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits | January 27, 2017 | February 28, 2020 |
| NCT04428099 | Unknown status | N/A | Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression | January 13, 2020 | July 12, 2022 |
| NCT03004521 | Unknown status | Phase 4 | Lithium Versus Quetiapine in Treatment Resistant Depression | November 2016 | August 2021 |
| NCT03626181 | Unknown status | N/A | Biomarkers of Theta Burst Stimulation in Major Depressive Disorder | July 6, 2018 | July 1, 2019 |
| NCT05008939 | Unknown status | N/A | Sevoflurane for Treatment-Resistant Depression | August 2021 | March 2022 |
| NCT02610712 | Unknown status | Phase 4 | Clinical Trial of the Use of Ketamine in Treatment Resistant Depression | May 2014 | |
| NCT05390593 | Unknown status | N/A | Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation | August 1, 2021 | July 31, 2023 |
| NCT03852160 | Withdrawn | Phase 3 | A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression | December 1, 2019 | July 25, 2021 |